Inmune Bio, Inc. — Director's Dealing 2021

Sep 8, 2021

SEC Form 4/A — Form 4/A

Issuer: Inmune Bio, Inc. (INMB)
CIK: 0001711754
Period of Report: 2021-06-10

Reporting Person: Xencor Inc (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-10	Common Stock	J	192533	$17.14	Acquired	1777533	Direct

Footnotes

F1: On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021.

F2: On June 14, 2021, Xencor filed a Form 4 which inadvertently reported that Xencor acquired 192,532 shares of common stock in the Option Cancellation Transaction. As reported in this amendment, Xencor actually acquired 192,533 shares of common stock in the Option Cancellation Transaction. The original Form 4 also inadvertently indicated that Xencor beneficially owned 1,777,532 shares of common stock following the Option Cancellation Transaction, but Xencor actually beneficially owned 1,777,533 shares of common stock.